[go: up one dir, main page]

PT97103A - Moleculas de acido nucleico isoladas e vacinas contra gp75 que as contem - Google Patents

Moleculas de acido nucleico isoladas e vacinas contra gp75 que as contem

Info

Publication number
PT97103A
PT97103A PT97103A PT9710391A PT97103A PT 97103 A PT97103 A PT 97103A PT 97103 A PT97103 A PT 97103A PT 9710391 A PT9710391 A PT 9710391A PT 97103 A PT97103 A PT 97103A
Authority
PT
Portugal
Prior art keywords
nucleic acid
fragment
isolated nucleic
acid molecules
vaccines
Prior art date
Application number
PT97103A
Other languages
English (en)
Other versions
PT97103B (pt
Inventor
Alan N Houghton
Setaluri Vijayasaradhi
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23976841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT97103(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of PT97103A publication Critical patent/PT97103A/pt
Publication of PT97103B publication Critical patent/PT97103B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
    • C12Y110/03—Oxidoreductases acting on diphenols and related substances as donors (1.10) with an oxygen as acceptor (1.10.3)
    • C12Y110/03001—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
    • C12Y114/16002—Tyrosine 3-monooxygenase (1.14.16.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/18—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with another compound as one donor, and incorporation of one atom of oxygen (1.14.18)
    • C12Y114/18001—Tyrosinase (1.14.18.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT97103A 1990-03-22 1991-03-21 Processo para a preparacao de moleculas isoladas de acido nucleico que codificam para gp75 e de vacinas para melanoma que as contem PT97103B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49743190A 1990-03-22 1990-03-22

Publications (2)

Publication Number Publication Date
PT97103A true PT97103A (pt) 1991-12-31
PT97103B PT97103B (pt) 1999-02-26

Family

ID=23976841

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97103A PT97103B (pt) 1990-03-22 1991-03-21 Processo para a preparacao de moleculas isoladas de acido nucleico que codificam para gp75 e de vacinas para melanoma que as contem

Country Status (20)

Country Link
US (2) US6168946B1 (pt)
EP (2) EP0965640A1 (pt)
JP (2) JP3336006B2 (pt)
AT (1) ATE187493T1 (pt)
AU (1) AU660412B2 (pt)
CA (1) CA2078773C (pt)
CZ (1) CZ290278B6 (pt)
DE (1) DE69131829T2 (pt)
DK (1) DK0522078T3 (pt)
ES (1) ES2141089T3 (pt)
FI (1) FI113786B (pt)
GR (1) GR3032804T3 (pt)
HU (1) HU218416B (pt)
IE (2) IE910820A1 (pt)
NO (1) NO311366B1 (pt)
NZ (1) NZ237532A (pt)
PL (3) PL169105B1 (pt)
PT (1) PT97103B (pt)
SK (1) SK282873B6 (pt)
WO (1) WO1991014775A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE910820A1 (en) * 1990-03-22 1991-09-25 Sloan Kettering Inst Cancer Gp75 as a tumor vaccine for melanoma
US7041801B1 (en) * 1995-06-07 2006-05-09 Vanderbilt University Antibodies binding to polypeptides encoded by developmentally-regulated endothelial cell locus-1
US7015312B1 (en) 1996-02-09 2006-03-21 The United States Of America As Represented By The Department Of Health And Human Services Antibodies to the protein product encoded by ORF3 of the TRP-1 gene and compositions and kits thereof
US7001600B1 (en) 1996-02-09 2006-02-21 The United States Of America As Represented By The Secretary Of Health And Human Services Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
US6083703A (en) * 1996-02-09 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
JP2004527449A (ja) * 2000-02-15 2004-09-09 リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア テロメラーゼ逆転写酵素を用いる癌を治療するための万能ワクチンと方法
US6613534B2 (en) 2001-03-20 2003-09-02 Wake Forest University Health Sciences MAP-2 as a determinant of metastatic potential
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
US20030157720A1 (en) * 2002-02-06 2003-08-21 Expression Technologies Inc. Protein standard for estimating size and mass
RU2287578C1 (ru) * 2005-04-22 2006-11-20 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Kor, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
RU2287575C1 (ru) * 2005-04-22 2006-11-20 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel P, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
RU2287577C1 (ru) * 2005-04-22 2006-11-20 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel IL, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
JP5213075B2 (ja) 2007-06-15 2013-06-19 ジェネラックス・コーポレイション 腫瘍の画像化および／または処置のための微生物
NZ587305A (en) 2008-03-12 2012-05-25 Imclone Llc Anti-tyrosinase-realted protein-1 (TYRP1) antibodies
RU2373280C1 (ru) * 2008-04-24 2009-11-20 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Gus, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
RU2390556C1 (ru) * 2008-12-26 2010-05-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Z, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
RU2402603C1 (ru) * 2009-02-12 2010-10-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Me, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4808704A (en) * 1981-09-30 1989-02-28 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to cell surface antigens of human malignant melanoma
US4806628A (en) * 1982-11-30 1989-02-21 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies against melanocytes
US4591572A (en) * 1983-04-01 1986-05-27 Sloan-Kettering Institute For Cancer Research Pigmentation associated, differentiation antigen of human melanoma and autologous antibody
USH819H (en) * 1984-04-30 1990-09-04 The United States Of America As Represented By The Secretary Of Energy Palladium-109 labeled anti-melanoma monoclonal antibodies
US4851510A (en) * 1984-11-30 1989-07-25 Wadley Technologies, Inc. Monoclonal antibodies to novel melanoma-associated antigens
US4798790A (en) * 1985-07-18 1989-01-17 Sloan-Kettering Institute Monoclonal antibody specific for a pigmentation associated antigen
US5141742A (en) * 1986-02-07 1992-08-25 Oncogen Vaccines against melanoma
US5262177A (en) * 1986-02-07 1993-11-16 Oncogen Recombinant viruses encoding the human melanoma-associated antigen
US5009995A (en) * 1986-10-27 1991-04-23 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to melanoma cells
US5059523A (en) * 1988-05-02 1991-10-22 Sloan-Kettering Institute For Cancer Research Cell-surface glycoproteins of human sarcomas
US5009495A (en) * 1989-05-26 1991-04-23 Williams Robert D Hinge for eyeglasses
AU645760B2 (en) 1989-08-04 1994-01-27 Berlex Laboratories, Inc. C-erbb-2 external domain: GP75
IE910820A1 (en) * 1990-03-22 1991-09-25 Sloan Kettering Inst Cancer Gp75 as a tumor vaccine for melanoma
US5262117A (en) * 1990-10-12 1993-11-16 Centro Sviluppo Settori Impiego S.R.L. Process for preparing thermoinsulating and/or structural formed articles and products so obtained
US6180604B1 (en) * 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin

Also Published As

Publication number Publication date
ES2141089T3 (es) 2000-03-16
PL169168B1 (pl) 1996-06-28
EP0522078A4 (en) 1993-05-26
US20050037462A1 (en) 2005-02-17
IE20000918A1 (en) 2001-05-30
EP0522078A1 (en) 1993-01-13
HK1014732A1 (en) 1999-09-30
JPH06501837A (ja) 1994-03-03
SK282873B6 (sk) 2003-01-09
WO1991014775A1 (en) 1991-10-03
AU660412B2 (en) 1995-06-29
NO923659D0 (no) 1992-09-21
CZ290278B6 (cs) 2002-07-17
NO923659L (no) 1992-11-06
CA2078773C (en) 2001-07-03
DE69131829D1 (de) 2000-01-13
CA2078773A1 (en) 1991-09-23
EP0965640A1 (en) 1999-12-22
HU218416B (hu) 2000-08-28
CS76091A3 (en) 1992-02-19
FI924222L (fi) 1992-09-21
PL289550A1 (en) 1992-07-27
GR3032804T3 (en) 2000-06-30
ATE187493T1 (de) 1999-12-15
NZ237532A (en) 1993-03-26
PT97103B (pt) 1999-02-26
JP2002241314A (ja) 2002-08-28
IE910820A1 (en) 1991-09-25
HUT62934A (en) 1993-06-28
DK0522078T3 (da) 2000-06-13
JP3336006B2 (ja) 2002-10-21
PL168235B1 (pl) 1996-01-31
FI113786B (fi) 2004-06-15
NO311366B1 (no) 2001-11-19
AU7690691A (en) 1991-10-21
FI924222A0 (fi) 1992-09-21
US6168946B1 (en) 2001-01-02
PL169105B1 (pl) 1996-06-28
DE69131829T2 (de) 2000-06-15
EP0522078B1 (en) 1999-12-08

Similar Documents

Publication Publication Date Title
PT97103A (pt) Moleculas de acido nucleico isoladas e vacinas contra gp75 que as contem
NO20013701L (no) HER-2/neu-fusjonsproteiner
FI852626A0 (fi) Menetelmä ihmisen tuumorinekroositekijän valmistamiseksi ja sitä koodaava DNA
WO2001008636A8 (en) Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
EE200100203A (et) Meetod immuunvastuse indutseerimiseks polüpeptiidse antigeeni vastu ja rakuga seotud polüpeptiidse antigeeni mahasurumiseks loomorganismil, selle meetodi kasutamine eesnäärme- ja rinnavähi raviks ning immunogeenne kompositsioon
NZ314058A (en) Use of ganglioside-KLH conjugate vaccines with QS-21 to treat cancer
WO2002012341A3 (en) Her-2/neu fusion proteins
PT92938A (pt) Imunogenes e processo para a preparacao de composicoes imunogenicas contra os peptidos da gastrina
BR9812472A (pt) Vacina especìfica de mamaglobina, processo para tratar um paciente com um tumor que expressa mamaglobina, e, polipeptìdeo isolado e purificado
WO1995031559A3 (en) Methods of inducing gene expression by ionizing radiation
DE69634912D1 (de) Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren
NO975730L (no) Metode for ökning av beskyttende immunresponser
BR9808881A (pt) Compostos para imunoterapia de câncer de próstata e métodos para seu uso
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
NO932101D0 (no) Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker
AU6941287A (en) Vaccines for human respiratory virus
WO1999065517A3 (en) Therapeutic compositions that produce an immune response by altering the antigen
Pellis et al. Specific tumor immunity induced with soluble materials: Purification of antigens inducing tumor resistance
DK0938329T3 (da) Immunogen TLP sammensætning
NO20005321L (no) Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette
EP0321094A3 (en) Treatment of factor viii inhibitors

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19910718

FG3A Patent granted, date of granting

Effective date: 19981102

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20080502